Vimarsana
Biggest News Aggregation in the World

Page 3 - Willy Simon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Willy Simon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Willy Simon Today - Breaking & Trending Today

OKYO Pharma Limited adds new non-executive to board - Vimarsana News

OKYO Pharma Limited adds new non-executive to board

Bernand Denoyer arrives with over 49 years of financial management experience

OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity - Vimarsana News

OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity

Message : Required fields LONDON, March 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that it has issued 250,000 ordinary shares of no par value (" Ordinary Shares"), credited as fully paid, at a price of 4.5p per share on the exercise of 250,000 options. Applications will be made to the FCA and to the London Stock Exchange for Admission in respect of all the 250,000 Ordinary Shares. It is expected that Admission will become effective, and that dealings in the new Ordinary Shares are expected to commence, at 8.00 a.m. on 3 March 2021. Following A...

OKYO Pharma : ISSUE OF EQUITY | MarketScreener - Vimarsana News

OKYO Pharma : ISSUE OF EQUITY | MarketScreener

1 March 2021 OKYO Pharma Limited today announces that it has issued 250,000 ordinary shares of no par value , credited as fully paid, at a price of 4.5p per share on the... | March 6, 2021

OKYO Pharma LTD: OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation - Vimarsana News

OKYO Pharma LTD: OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation

(1) LONDON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company"), a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and chronic ocular pain, today announced that patent No. 10,899,796 entitled "Compounds and Methods for Treating Pain" was issued by the United States Patent and Trademark Office ("USPTO") on January 26, 2021. This patent covers a class of bovine adrenal medulla (BAM) peptides linked to specific lipids that demonstrate potential for treating symptoms of neuropathic pain, ocular pain, ocular inflammat...

Investegate |OKYO Pharma Limited Announcements | OKYO Pharma Limited: Directorate Change - Vimarsana News

Investegate |OKYO Pharma Limited Announcements | OKYO Pharma Limited: Directorate Change

7 January 2021 OKYO Pharma Limited ("OKYO" or the "Company") today announces that Gabriele Cerrone has been appointed as a non-executive chairman of the company and Dr Gary S. Jacob has been appointed as Chief Executive Officer and director of the company, both with immediate effect. Gabriele Cerrone (age: 48) Mr Cerrone has a successful track record and extensive experience in the financing and restructuring of micro-cap biotechnology companies. He has founded ten biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has taken seven of thes...